Skip to main content
S&P 5007,592.40-0.35%DOW52,297.09-0.36%NASDAQ25,366.09-0.39%BTC$69,172.00-4.64%ETH$1,954.94-2.37%GOLD$3,894.20+0.23%OIL$88.54-0.23%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARWR

Arrowhead Pharmaceuticals, Inc.

Healthcare · Biotechnology

$47.15

Down-$2.21 (-4.48%)

Updated Nov 13, 2026, 1:00 PM

SID Score

3.8/10

Composite research score

Smart Money

62/100

Neutral

Market cap
8.86B
P/E ratio
43.81
Dividend yield
0.00%
52-week range
$37.06 – $95.49
Volume
2.16M
Avg. volume
3.18M

Price performance · ARWR

ARWR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

ARWR closed at $47.15 after 21 trading sessions, down 19.40% for the selected period.

Last close
$47.15
Period change
-19.40%
Period low
$47.15
Period high
$61.65
Daily close
View OHLC price history
ARWR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$48.99$48.99$46.98$47.152.16M
Nov 11, 2026$49.65$49.74$47.66$49.362.53M
Nov 10, 2026$48.61$50.56$47.89$49.002.64M
Nov 9, 2026$52.49$53.625$46.4508$49.248.06M
Nov 6, 2026$58.21$58.71$57.00$58.161.36M
Nov 5, 2026$61.65$61.73$57.235$57.461.81M
Nov 4, 2026$61.75$62.00$59.06$61.651.62M
Nov 3, 2026$59.39$60.89$59.245$59.531.33M
Nov 2, 2026$60.55$61.17$59.405$59.571.31M
Oct 30, 2026$59.75$61.50$58.74$59.901.12M
Oct 29, 2026$60.74$61.88$59.75$60.491.28M
Oct 28, 2026$58.64$60.24$58.201$60.211.25M
Oct 27, 2026$59.02$60.56$58.01$59.032.12M
Oct 26, 2026$58.43$59.625$58.17$58.98979.89K
Oct 23, 2026$58.15$58.40$56.56$58.02871.82K
Oct 22, 2026$58.06$59.90$56.97$58.361.04M
Oct 21, 2026$59.72$60.46$58.82$58.841.37M
Oct 20, 2026$56.93$59.57$56.915$58.921.74M
Oct 19, 2026$56.96$57.30$56.05$57.231.65M
Oct 16, 2026$58.45$58.45$55.83$55.901.77M
Oct 15, 2026$58.50$59.3955$57.40$58.502.01M

Latest ARWR news

The latest Smart Investors Daily articles mentioning ARWR.

Stock researchCompany · Overview

ARWR research

Overview

Company profile and research snapshot.

Company profile

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$71.00
Implied upside
—
Analysts
—
ARWR recent ratings
DateFirmRatingTarget
Oct 15, 2026Chardan CapitalBuy—
Oct 15, 2026HC Wainwright & Co.Buy—
Sep 24, 2026Goldman SachsNeutral—
Sep 8, 2026CitigroupBuy—
Sep 1, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 27, 2026

Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its growth stage, fueled by increased R&D in protein augmentation, gene therapies, and rising awareness. Established treatments include intravenous augmentation therapy, with inhaled formulations and emerging gene-editing therapies in development. North America leads the market thanks to strong infrastructu

Yahoo · Feb 18, 2026

Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. The tenth stock on our list is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR). TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating. The firm noted that […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By